DeepMed Research

TAIHO PHARMACEUTICAL CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 1963-01-01

Employees: 1K

Market Cap: -

Website: http://www.taiho.co.jp

Clinical Trials

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: S-1 plus LV (The combination therapy of S-1 and Leucovorin)

First Posted Date: 2009-05-01

Last Posted Date: 2012-01-18

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 73

Registration Number: NCT00891332

Locations: 🇨🇳
PLA 307 Hospital, No.4 Division of Oncology, East Avenue, Fengtai District, Beijing, China
🇨🇳
Beijing Cancer Hospital, Digestive System Medicine Department, Fucheng Road, Haidian District, Beijing, China
🇨🇳
Shanghai Fudan University Cancer Hospital, Division of Oncology, Dong An Road, Shanghai, China

and more 3 locations

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Phase 2

Terminated

Conditions: Advanced Colorectal Cancer

Interventions: Drug: TAS-109

First Posted Date: 2009-01-16

Last Posted Date: 2012-04-23

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT00824161

Locations: 🇺🇸
NYU Cancer Institute, East 34th Street, New York, New York, United States
🇺🇸
The Center for Cancer and Blood Disorders, West Magnolia Avenue, Fort Worth, Texas, United States
🇺🇸
The University of Texas M.D. Anderson Cancer Center, Holcombe Boulevard, Houston, Texas, United States

Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Orantinib (TSU-68)

First Posted Date: 2008-11-02

Last Posted Date: 2012-03-26

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 35

Registration Number: NCT00784290

Locations: 🇯🇵
Chiba University Hospital, Inohana Chuo-ku Chiba, Chiba, Japan

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

Phase 3

Completed

Conditions: Cervical Cancer

Interventions: Drug: S-1 + Cisplatin (arm A)
Drug: Cisplatin (arm B)

First Posted Date: 2008-10-10

Last Posted Date: 2019-06-21

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 375

Registration Number: NCT00770874

Locations: 🇨🇳
Chang Gung Medical Foundation- Linkou, Fu-Hsing Saint Kuei Shan Hsiang, TaoYuan Hsien, Taiwan
🇯🇵
Yanagawa Hospital, Chikushimachi, Yanagawa, Fukuoka, Japan
🇯🇵
Cancer Institute Hospital, Ariake, Koto-ku, Tokyo, Japan

and more 1 locations

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: TAS-106

First Posted Date: 2008-08-19

Last Posted Date: 2012-09-05

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT00737360

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Orleans Street, Baltimore, Maryland, United States
🇸🇬
National University Hospital, Lower Kent Ridge Road, Singapore
🇨🇳
National Taiwan University Hospital Department of Oncology, No. 1, Chang-De Street , Taipei, Taiwan

and more 2 locations

Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
Drug: mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)

First Posted Date: 2008-07-25

Last Posted Date: 2012-11-01

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 107

Registration Number: NCT00721916

Locations: 🇯🇵
Shizuoka Cancer Center, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, Japan

Phase II Study of ABI-007 for Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: ABI-007

First Posted Date: 2008-04-18

Last Posted Date: 2012-01-18

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 56

Registration Number: NCT00661167

Locations: 🇯🇵
Kochi Health Sciences Center, Kochi, Japan
🇯🇵
Aichi Cancer Center, Nagoya, Aichi, Japan
🇯🇵
National Kyusyu Cancer Center, Fukuoka, Japan

and more 7 locations

Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal, Cancer

Interventions: Drug: S-1, Irinotecan, Bevacizumab

First Posted Date: 2007-12-07

Last Posted Date: 2012-11-02

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT00569335

Locations: 🇯🇵
National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan

Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: S-1, Bevacizumab

First Posted Date: 2007-12-07

Last Posted Date: 2012-11-02

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 56

Registration Number: NCT00569699

Locations: 🇯🇵
Osaka Medical College Hospital, Takatsuki, Osaka, Japan

Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: S-1, Irinotecan, Bevacizumab

First Posted Date: 2007-12-07

Last Posted Date: 2012-11-02

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 53

Registration Number: NCT00569790

Locations: 🇯🇵
Hokkaido University Hospital (Hokkaido Gastrointestinal Cancer Study Group), Sapporo, Hokkaido, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy